{"id":4455,"date":"2025-09-09T13:40:50","date_gmt":"2025-09-09T10:40:50","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4455"},"modified":"2025-09-09T13:43:30","modified_gmt":"2025-09-09T10:43:30","slug":"solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/solid-biosciences-sgt-003-gene-therapy-phase-3-clinical-trial-nct07160634\/","title":{"rendered":"Solid Biosciences startet klinische Phase-3-Studie zur Gentherapie SGT-003 (IMPACT DUCHENNE) bei gehf\u00e4higen M\u00e4nnern"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Die Phase-3-Studie (NCT07160634) der von Solid Biosciences entwickelten Gentherapie SGT-003 soll im Oktober 2025 beginnen und im Januar 2029 abgeschlossen sein.<\/strong> An der Phase-3-Studie SGT-003 werden 80 gehf\u00e4hige M\u00e4nner teilnehmen. Dar\u00fcber hinaus wurden die Studienorte noch nicht bekannt gegeben. <strong>Mehr lesen<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/de\/faq-solid-biosciences-sgt-003-gene-therapy\/\" target=\"_blank\" rel=\"noreferrer noopener\">H\u00e4ufig gestellte Fragen zur Solid Biosciences SGT-003-Gentherapie<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">SGT-003 Gentherapie Phase 3 Studie \u2013 NCT07160634 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Dies ist eine doppelblinde, placebokontrollierte Phase-3-Studie mit dem prim\u00e4ren Ziel, die Wirksamkeit einer einzelnen intraven\u00f6sen Infusion von SGT-003 bei p\u00e4diatrischen, ambulanten m\u00e4nnlichen Teilnehmern mit DMD zu untersuchen. Zu den sekund\u00e4ren Zielen geh\u00f6rt die Bewertung weiterer Wirksamkeits- und Sicherheitsergebnisse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienbeginn (voraussichtlich)<\/strong>: 2025-10<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Prim\u00e4rer Abschluss (gesch\u00e4tzt)<\/strong>: 2029-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienabschluss (gesch\u00e4tzt)<\/strong>: 2034-01<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Anzahl der Teilnehmer (gesch\u00e4tzt)<\/strong>: 80<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studientyp<\/strong>: Interventionell<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Standorte<\/strong>: Noch keine Standortdaten.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Studienberechtigte Altersgruppen<\/strong>: 7 bis 11 Jahre (gehf\u00e4hige M\u00e4nner)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Wichtigste Ein- und Ausschlusskriterien. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07160634\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07160634<\/a> \u2013<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">So nehmen Sie an der klinischen Studie SGT-003 teil<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Um an der klinischen Studie SGT-003 Phase 3 teilzunehmen, k\u00f6nnen Sie die unten stehenden Kontaktinformationen verwenden.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Name<\/strong>: Solid Biosciences<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Telefonnummer<\/strong>: 6173374680<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-Mail<\/strong>: clinicaltrials@solidbio.com<\/p>","protected":false},"excerpt":{"rendered":"<p>The phase 3 study (NCT07160634) of the SGT-003 gene therapy developed by Solid Biosciences is expected to begin in October 2025 and be completed in January 2029. The SGT-003 Phase 3 study will include 80 ambulant males, moreover the study locations have not yet been shared. Read More: Frequently Asked Questions About Solid Biosciences SGT-003 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4459,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,242,61,419,110,170,109],"class_list":["post-4455","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-clinical-trials","tag-gene-therapy","tag-impact-duchenne","tag-sgt-003","tag-sgt-003-gene-therapy","tag-solid-biosciences"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=4455"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/4455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/4459"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=4455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=4455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=4455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}